Biotechnology · Healthcare
David Rodman
Equibles does not estimate personal net worth.
Get an email with a short summary when Mineralys Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get MLYS alertsAbout David Rodman
The proxy statement of Mineralys Therapeutics, Inc. reports total compensation of $2,204,704 for David Rodman in fiscal 2025, including a base salary of $533,000. Disclosed compensation is on record for 4 fiscal years. David Rodman has spoken on 4 earnings calls across 1 company, most recently for Mineralys Therapeutics, Inc. on November 10, 2025. Mineralys Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Mineralys Therapeutics, Inc. includes Jon Congleton (CEO and Board Member), Glenn P. Sblendorio (Chairman), Alexander Gold (Board Member) and 6 others.
David Rodman on recent calls
“We followed what we agreed upon with the FDA regarding the approach to handle missing data. As you know, figures exceeding 15% and especially 20% can cause significant issues, sometimes preventing the agency from evaluating those trials.”
“Picking up from where Jon just left off, discussing the KOL event we had last quarter, I agree that there were a lot of great topics discussed.”
“So the question, just to reiterate it and let me know if I've got it right, is are we going to encounter less confusion or less clarity, let's say at 12 weeks, because we have some people on 50 mg straight through and others who could have their dose increased to 100 mg?”
“The first inquiry was about the powering for the Advance trial, specifically regarding the placebo expectations. I want to remind you that in Advance, we're using 24-hour ambulatory blood pressure monitoring as the primary measure.”
Affiliation history
-
Mineralys Therapeutics, Inc. (MLYS)
Source not stated
Current
Company network
Leadership on record at Mineralys Therapeutics, Inc.
- Jon Congleton CEO, Board Member
- Glenn P. Sblendorio Chairman
- Alexander Gold Board Member
- Alexander M. Gold, M.D. Board Member
- Brian Taylor Slingsby Board Member
- Daphne Karydas Board Member
- Kristine Peterson Board Member
- Lonnel Coats Board Member
- Srinivas Akkaraju Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Mineralys Therapeutics, Inc. (MLYS) | Chief Medical Officer | $533,000 | $2,204,704 |
| 2024 | Mineralys Therapeutics, Inc. (MLYS) | Chief Medical Officer | $520,000 | $2,877,749 |
| 2023 | Mineralys Therapeutics, Inc. (MLYS) | Chief Medical Officer | $500,000 | $2,334,207 |
| 2022 | Mineralys Therapeutics, Inc. (MLYS) | Chief Medical Officer | $411,458 | $1,106,507 |